Aug. 1 at 5:33 AM
$NVO $HIMS $WW $LLY $NVDA
https://www.ainvest.com/news/alhemo-fda-approval-hemophilia-inhibitors-game-changer-novo-nordisk-rare-disease-portfolio-2508/
Approval on July 31, 2025, as a once-daily subcutaneous hemophilia A/B prophylaxis for adults and adolescents (12+ years) without inhibitors.
– The TFPI inhibitor demonstrated 86% and 79% bleeding reduction in hemophilia A/B patients, respectively, with 70.9% patient preference over existing treatments.
– Alhemo targets a
$9.09B U.S. hemophilia prophylaxis market (projected 2030 value) by addressing adherence challenges with its prefilled pen-injector and competing directly with Hemlibra and Hyrnpavzi.
– Analysts forecast
$1–2B annual sales by 2030 with 20–30% market penetration, positioning Novo Nordisk to capitalize on the 6.9% CAGR growth in prophylactic treatment adoption.
